Watanabe, Haruki
Sada, Ken-ei
Harigai, Masayoshi
Amano, Koichi
Dobashi, Hiroaki
Takasaki, Yoshinari
Fujimoto, Shouichi
Atsumi, Tatsuya
Yamagata, Kunihiro
Homma, Sakae
Arimura, Yoshihiro
Makino, Hirofumi
,
,
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (nannti-ippann-004, -018)
Japan Agency for Medical Research and Development (17ek0109104, 17ek0109121, JP18ek0109360)
Article History
Received: 13 September 2020
Accepted: 15 January 2021
First Online: 4 March 2021
Competing interests
: KS received speaker’s fee from Astra Zeneca K.K. MH has received unrestricted research grants from AbbVie Japan GK, Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Eisai Co., Ltd., Nippon Kayaku Co., Ltd.; Mitsubishi Tanabe Pharma Co.; and Teijin Pharma Ltd. MH has received speaker’s fee from Boehringer-ingelheim, Kissei Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Chugai Pharmaceutical Co., Ltd. MH is a consultant for AbbVie, Boehringer-ingelheim, Kissei Pharmaceutical Co., Ltd. and Teijin Pharma. HM is a consultant for AbbVie, Boehringer-Ingelheim and Teijin. The other authors declare no competing interests.